Alzheimer’s Disease/Dementia News

Drugs that target the noradrenergic system may improve cognition and apathy in patients with dementia or mild cognitive impairment caused by Alzheimer’s disease but have little effect on attention or episodic memory, researchers reported.

PTSD was associated with accelerated decline in cognitive function in middle-aged women, researchers reported in JAMA Network Open.

A thin optical fiber shows promise for use in minimally invasive deep tissue studies in brains affected by Alzheimer’s disease, researchers reported in APL Photonics.

Mdoloris, a company specializing in medical pain monitoring technologies, announced its latest device, a bracelet that can record and track the pain and well-being of those who are unable to verbalize or indicate what they are feeling.

Men who experience behavioral changes, such as apathy or hallucinations, are at a faster risk for cognitive decline compared with women, findings published in the Journal of Alzheimer’s Disease showed.

Acadia Pharmaceuticals Inc. announced the outcome of the FDA advisory committee meeting on the use of pimavanserin for treating hallucinations and delusions associated with Alzheimer’s disease psychosis.

Those diagnosed with dementia faced a greater risk for COVID-19 breakthrough infections and hospitalizations than those without, according to a study published in Alzheimer’s & Dementia.

NEW ORLEANS – Clinicians need to do a better job screening for mild cognitive impairment, Brent P. Forester, MD, MSc, said at the American Psychiatric Association annual meeting.

NEW ORLEANS – The American Psychiatric Association DSM steering committee gathered at the APA annual meeting to review proposed changes to the manual, committee chair Paul S. Appelbaum, MD, said.

NEW ORLEANS – For the first time in 3 years, the American Psychiatric Association will host its annual meeting in person, May 21 to 25 in New Orleans, with social determinants of mental health as the conference theme.